Evidence map›Paper›PMID 42295144›Full record

ArticleBiotechnology progress

Viscosity of concentrated mRNA solutions: Implications for downstream processing.

Amin Javidanbardan, Fatemeh Najafi, Ziqiao Wang, Andrew L Zydney

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biotechnology progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Amin JavidanbardanDepartment of Chemical Engineering, The Pennsylvania State University, University Park, Pennsylvania, USA.ORCID https://orcid.org/0000-0001-5146-4698
Fatemeh NajafiDepartment of Chemical Engineering, The Pennsylvania State University, University Park, Pennsylvania, USA.
Ziqiao WangDepartment of Chemical Engineering, The Pennsylvania State University, University Park, Pennsylvania, USA.
Andrew L ZydneyDepartment of Chemical Engineering, The Pennsylvania State University, University Park, Pennsylvania, USA.ORCID https://orcid.org/0000-0003-1865-9156

Funding

FDA HHS 75F40122C00200U.S. Food and Drug Administration 75F40122C00200
6 · The paper itself

Abstract

Messenger RNA (mRNA) therapeutics can be used to protect against infectious disease and for the treatment of cancers and genetic disorders. In order to obtain the desired therapeutic dosage, it is necessary to concentrate the mRNA to levels where the viscosity of the mRNA solutions can become significant. However, there is currently no quantitative data on the viscosity of these concentrated mRNA solutions. Experiments were performed with two model mRNA constructs: a firefly luciferase (Fluc) mRNA (2.117 kb) and a self-amplifying RNA (9.442 kb) over a wide range of concentrations. The viscosity of the larger saRNA was more than 140 mPa·s at a concentration of 28 mg/mL, which is more than 10× larger than that for the Fluc mRNA under the same conditions. The viscosity was a weak function of shear rate (from 10 to 100 s

Indexed as

RNA, MessengerViscosityRNA, Messengerdownstream processingmRNAsaRNAultrafiltrationviscosity

Identifiers

PMID42295144
PMCPMC13636608

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.